Jazz Pharmaceuticals Plc - Q1 2011 10-Q Summary
Business Context and Reporting Period
This report covers the quarterly period ended March 31, 2011. Jazz Pharmaceuticals is a specialty pharmaceutical company focused on the development and commercialization of products for unmet medical needs. The company operates in a single segment and relies heavily on two marketed products: Xyrem (sodium oxybate) for narcolepsy and Luvox CR (fluvoxamine maleate) for obsessive-compulsive disorder. Xyrem accounted for 86% of net product sales in the quarter.
Key Financial Metrics
| Metric | Q1 2011 | Q1 2010 |
|---|---|---|
| Total Revenues | $50.9 million | $35.2 million |
| Net Income | $21.8 million | $1.5 million |
| Diluted EPS | $0.48 | $0.04 |
| Operating Cash Flow | $24.4 million | $6.5 million |
| Cash and Equivalents (End of Period) | $65.1 million | $19.0 million |
| Long-Term Debt Outstanding | $37.5 million | $116.5 million |
| Interest Expense | $0.8 million | $5.8 million |
Margins: Operating income was $22.6 million, representing a significant improvement over the $7.2 million reported in the prior year. Cost of product sales as a percentage of sales decreased to 6% from 8% in the prior year.
Material Changes vs. Prior Period
- Revenue Growth: Total revenues increased 45% year-over-year, driven primarily by a 49% increase in Xyrem sales (due to price increases and volume growth) and a 29% increase in Luvox CR sales.
- Profitability Surge: Net income increased 1,390% to $21.8 million. This was largely driven by a reduction in interest expense (down 87%) due to the repayment of senior secured notes and a decrease in R&D spending (down 41%).
- Debt Reduction: The company significantly reduced its debt load, with long-term debt principal dropping from $116.5 million in Q1 2010 to $37.5 million in Q1 2011.
- Expense Management: R&D expenses decreased by $2.5 million, primarily due to reduced spending on the JZP-6 product candidate following a Complete Response Letter from the FDA.
Guidance, Outlook, and Risks
Outlook and Commentary: Management expects total product sales to increase in 2011 compared to 2010, though the growth rate may be lower than in 2010. R&D spending is expected to be significantly lower in 2011, focusing primarily on headcount. The company does not intend to move forward with additional JZP-6 clinical studies for fibromyalgia unless regulatory requirements are significantly reduced. The company is evaluating the future of the JZP-8 intranasal clonazepam program.
Risks and Contingencies:
- Generic Competition: Roxane Laboratories filed an Abbreviated New Drug Application (ANDA) for a generic version of Xyrem. Jazz has sued Roxane for patent infringement. If approved, generic entry would adversely affect sales.
- Regulatory Issues: The FDA issued a Form 483 observation regarding the company's adverse event reporting system after discovering 74 unreported deaths of patients prescribed Xyrem between 2003 and 2010. The company has reported these cases and is implementing corrective actions.
- Supply Chain: The company relies on sole-source suppliers for drug substances and manufacturing. Xyrem production is subject to DEA quotas, which could limit supply.
- Customer Concentration: One customer, Express Scripts, accounted for 84% of total revenues in Q1 2011.
Investor Verification Checklist
- Verify the status and potential outcome of the patent infringement litigation against Roxane Laboratories regarding Xyrem.
- Confirm the FDA's response to the Form 483 observations and the company's corrective action plan regarding adverse event reporting.
- Monitor the company's ability to secure sufficient DEA quotas for sodium oxybate to meet demand.
- Assess the impact of the 84% revenue concentration with Express Scripts on pricing power and distribution stability.
- Review the progress of the JZP-8 program and the decision-making timeline regarding its continuation.